Effect of metformin on polycystic ovarian syndrome

Effect of metformin on lipid profile in women with polycystic ovarian

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012100110981N1

Enrollment

100

Registered

2012-12-02

Start date

2009-02-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polycydstic ovarian syndrome. Poly cystic ovarian syndrom

Interventions

Intervention 1: In control group: mint tablet three times per day (TDS) with every meal orally for 6 month. Intervention 2: In intervention group: tablet Metformin, 500mg three times every day (TDS) w

Treatment - Drugs

In control group: mint tablet three times per day (TDS) with every meal orally for 6 month

In intervention group: tablet Metformin, 500mg three times every day (TDS) with every meal for six month

Eligibility

Sex/Gender

Female

Age

17 Years to 31 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:Patients with oligomenorrhea hyperandrogenism including a hirsutism , exclusion craiteria: hype rprolactinoma , abnormal thyroid test and premature ovarian frailer, diabetes, coshing syndrome according to Basal clinical endocrine

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Lipides profile of plasma. Timepoint: before intervention ,three and six month after intervention. Method of measurement: mg/dl.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Masoumeh Rezaie

Kurdistan University of Medical Sciences

masomehrezaei@muk.ac.irmrezaie2001@yahoo.com+98 87 1323 9345

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026